^
Association details:
| Biomarker: | HR positive + BRCA2 mutation |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
Published date:
07/20/2023
Excerpt:
Tissue was collected from 89 patients with HR+/HER2- MBC, including those with recurrent and/or metastatic disease, receiving palbociclib plus an aromatase inhibitor or fulvestrant...Likewise, the presence of mutated BRCA1/2 was associated with shorter PFS (HR = 2.67; p = 0.012, q = 0.049). Mutation of TP53 (HR = 3.92; p < 0.001, q < 0.001) and APOBEC signature S13 (HR = 3.19; p = 0.002, q = 0.012) were associated with shorter PFS.
Secondary therapy:
Aromatase inhibitor; fulvestrant
DOI:
https://doi.org/10.1186/s13073-023-01201-7
Source:
Title:
Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
Published date:
01/29/2022
Excerpt:
High TMB, TP53 mutation, PTEN loss of function mutation and RB1 pathway alteration showed worse prognosis in palbociclib plus ET arm. Patients with BRCA2 pathogenic mutations showed worse prognosis regardless of PAM50 subtypes. AURKA mutation/amplification, BRIP1/MYC/RAD51C amplification were significantly associated to the patients with short PFS <6 month.
DOI:
10.1016/j.breast.2022.01.014
